Dimas Timmers
CEO @ Raras Health
Dimas Timmers is a startup investor at Raras Health.
Last updated:
For AI agents: llms.txt
About Raras Health
Raras Health is a Brazilian health technology company building AI infrastructure for rare disease diagnosis. An estimated 300 million people worldwide live with one of more than 7,000 known rare diseases, and the average patient endures a diagnostic odyssey of five to seven years across multiple specialists before receiving an accurate diagnosis.Raras was founded to compress that timeline through a combination of advanced AI, biomedical knowledge engineering, and clinical partnerships.The company's flagship product, My Scientist, is a multi-agent on-premise AI platform that supports clinicians in evaluating complex undiagnosed cases. It combines specialized agents for phenotype extraction, genomics analysis, knowledge-graph reasoning, literature review, differential diagnosis, and treatment guidance. On RareBench, the leading public benchmark for rare disease diagnostic AI, My Scientist achieves Recall@1 of 66.7% and Recall@5 of 86.7%, placing it among the strongest rare disease diagnostic systems published to date. The platform is deployed on-premise to meet hospital data governance requirements and is powered by open-source foundation models served through vLLM, alongside Araras-HPO, the company's proprietary Portuguese-language biomedical language model.Raras Enciclopédia serves as the underlying knowledge and ontology layer, integrating data on more than 10,468 rare diseases across a graph of over 927,000 nodes and 5.4 million edges. The encyclopedia consolidates international ontologies (HPO, Orphanet, OMIM, MONDO) with curated clinical knowledge into a unified resource that powers both clinical decision support and patient-facing applications. Raras is co-founded by Dimas Timmers (CEO), a deep-tech AI entrepreneur with prior experience at Antler and Meta, and previously founder of Nindoo, an AI lab focused on federated learning in healthcare; Dr. Alexandre Kawassaki (CMO), a rare disease specialist at Hospital das Clínicas da Universidade de São Paulo and LinkedIn Top Voice in Healthcare; and Dr. João Bosco Oliveira Filho (CSO), holder of dual PhDs from USP and the University of Amsterdam, post-doctorate at the U.S. National Institutes of Health, founder of NeoGenomica, and former principal investigator of the Rare Genomes Project at Hospital Israelita Albert Einstein.Raras maintains institutional partnerships with Hospital das Clínicas da Universidade de São Paulo, Instituto Jô Clemente. The company is headquartered in Brazil, with European expansion underway in Lisbon, Portugal.Menos sorte. Mais respostas. (Less luck. More answers.)
Raras Health Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexandre Kawassaki
CMO
|
|||
|
Dimas Timmers
CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
